Latency reversal and viral clearance to cure HIV-1

Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques

(2016) Gregory Q. Del Prete et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

In vivo platforms for analysis of HIV persistence and eradication

(2016) J. Victor Garcia   JOURNAL OF CLINICAL INVESTIGATION

Macrophages sustain HIV replication in vivo independently of T cells

(2016) Jenna B. Honeycutt et al.   JOURNAL OF CLINICAL INVESTIGATION

Quantitation of Productively Infected Monocytes and Macrophages of Simian Immunodeficiency Virus-Infected Macaques

(2016) Claudia R. Avalos et al.   JOURNAL OF VIROLOGY

Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection

(2016) Beatrice Ondondo et al.   MOLECULAR THERAPY

Persistent HIV-1 replication maintains the tissue reservoir during therapy

(2016) Ramon Lorenzo-Redondo et al.   NATURE

Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E

(2016) S. G. Hansen et al.   SCIENCE

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

(2016) Glen M. Chew et al.   PLoS Pathogens

Broadly Neutralizing Antibodies for HIV Eradication

(2016) Kathryn E. Stephenson et al.   Current HIV/AIDS Reports

Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery

(2015) Anthony R. Cillo et al.   AIDS

Understanding HIV Latency: The Road to an HIV Cure

(2015) Matthew S. Dahabieh et al.   Annual Review of Medicine

Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy

(2015) Gregory Q. Del Prete et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV-1 Integration Landscape during Latent and Active Infection

(2015) Lillian B. Cohn et al.   CELL

Dual-Affinity Re-Targeting proteins direct T cell–mediated cytolysis of latently HIV-infected cells

(2015) Julia A.M. Sung et al.   JOURNAL OF CLINICAL INVESTIGATION

Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir

(2015) Julia A. Sung et al.   JOURNAL OF INFECTIOUS DISEASES

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies

(2015) Amanda M. Crooks et al.   JOURNAL OF INFECTIOUS DISEASES

H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat inEx VivoCultures of Resting CD4+T Cells

(2015) Manoj K. Tripathy et al.   JOURNAL OF VIROLOGY

HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses

(2015) Cristina Andrés et al.   JOURNAL OF VIROLOGY

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations

(2015) Kai Deng et al.   NATURE

B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers

(2015) Yoshinori Fukazawa et al.   NATURE MEDICINE

Viremic Relapse after HIV-1 Remission in a Perinatally Infected Child

(2015) Katherine Luzuriaga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toward an HIV vaccine: A scientific journey

(2015) A. S. Fauci et al.   SCIENCE

Activation and lysis of human CD4 cells latently infected with HIV-1

(2015) Amarendra Pegu et al.   Nature Communications

Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells

(2015) Derek D. Sloan et al.   PLoS Pathogens

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

(2015) Gilles Darcis et al.   PLoS Pathogens

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

(2015) Gemma Hancock et al.   PLoS Pathogens

Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection

(2015) Natalia Soriano-Sarabia et al.   PLoS Pathogens

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study

(2015) Julian H Elliott et al.   Lancet HIV

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

(2014) Ariel Halper-Stromberg et al.   CELL

Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines

(2014) Tomáš Hanke   EXPERT OPINION ON BIOLOGICAL THERAPY

A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen

(2014) Scott M. Hammer et al.   HIV CLINICAL TRIALS

Quantitation of Replication-Competent HIV-1 in Populations of Resting CD4+ T Cells

(2014) N. Soriano-Sarabia et al.   JOURNAL OF VIROLOGY

Shot in the HAART: vaccine therapy for HIV

(2014) Merlin L Robb et al.   LANCET INFECTIOUS DISEASES

HIV-1 persistence in CD4+ T cells with stem cell–like properties

(2014) Maria J Buzon et al.   NATURE MEDICINE

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

(2014) C Korin Bullen et al.   NATURE MEDICINE

Eradicating HIV-1 infection: seeking to clear a persistent pathogen

(2014) Nancie M. Archin et al.   NATURE REVIEWS MICROBIOLOGY

Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy

(2014) A. R. Cillo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune Activation with HIV Vaccines

(2014) A. S. Fauci et al.   SCIENCE

Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection

(2014) T. A. Wagner et al.   SCIENCE

Specific HIV integration sites are linked to clonal expansion and persistence of infected cells

(2014) F. Maldarelli et al.   SCIENCE

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

(2014) Julian H. Elliott et al.   PLoS Pathogens

Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART

(2014) Paul W. Denton et al.   PLoS Pathogens

Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes

(2014) Richard Brad Jones et al.   PLoS Pathogens

Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy

(2014) Mary F. Kearney et al.   PLoS Pathogens

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure

(2013) Ya-Chi Ho et al.   CELL

Immune activation and HIV persistence: implications for curative approaches to HIV infection

(2013) Nichole R. Klatt et al.   IMMUNOLOGICAL REVIEWS

Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire

(2013) Joseph P. Casazza et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 Conserved-Element Vaccines: Relationship between Sequence Conservation and Replicative Capacity

(2013) M. Rolland et al.   JOURNAL OF VIROLOGY

HIV-1 Gag Cytotoxic T Lymphocyte Epitopes Vary in Presentation Kinetics Relative to HLA Class I Downregulation

(2013) A. Balamurugan et al.   JOURNAL OF VIROLOGY

Immune clearance of highly pathogenic SIV infection

(2013) Scott G. Hansen et al.   NATURE

Resistance Mutations and CTL Epitopes in Archived HIV-1 DNA of Patients on Antiviral Treatment: Toward a New Concept of Vaccine

(2013) Jennifer Papuchon et al.   PLoS One

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

(2013) J. A. Horwitz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time

(2013) L. Josefsson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms

(2013) S. G. Hansen et al.   SCIENCE

An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients

(2013) Celsa A. Spina et al.   PLoS Pathogens

Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies

(2013) Susanne Eriksson et al.   PLoS Pathogens

Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient

(2013) Steven A. Yukl et al.   PLoS Pathogens

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients

(2012) Alejandro Vallejo et al.   AIDS

Prospects for Treatment of Latent HIV

(2012) K M Barton et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Control of HIV Latency by Epigenetic and Non-Epigenetic Mechanisms

(2012) Jonathan Karn et al.   CURRENT HIV RESEARCH

Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation

(2012) Liang Shan et al.   IMMUNITY

Early Antigen Presentation of Protective HIV-1 KF11Gag and KK10Gag Epitopes from Incoming Viral Particles Facilitates Rapid Recognition of Infected Cells by Specific CD8+ T Cells

(2012) H. N. Kloverpris et al.   JOURNAL OF VIROLOGY

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

(2012) Florian Klein et al.   NATURE

Therapeutic vaccines against HIV infection

(2012) Felipe García et al.   Human Vaccines & Immunotherapeutics

Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir

(2011) Deborah Persaud et al.   AIDS

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study

(2011) Josep M Llibre et al.   ANTIVIRAL THERAPY

No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy

(2011) Rajesh T. Gandhi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Definition of the viral targets of protective HIV-1-specific T cell responses

(2011) Beatriz Mothe et al.   Journal of Translational Medicine

Generation of HIV Latency in Humanized BLT Mice

(2011) P. W. Denton et al.   JOURNAL OF VIROLOGY

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

(2009) Brigitte Autran et al.   AIDS

Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid

(2009) Nancie M. Archin et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic

(2009) Samuel Broder   ANTIVIRAL RESEARCH

Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells

(2009) Xavier Contreras et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

No Evidence for Decay of the Latent Reservoir in HIV‐1–Infected Patients Receiving Intensive Enfuvirtide‐Containing Antiretroviral Therapy

(2009) Rajesh T. Gandhi et al.   JOURNAL OF INFECTIOUS DISEASES

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

Long-Term Control of HIV byCCR5Delta32/Delta32 Stem-Cell Transplantation

(2009) Gero Hütter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

(2009) J. B. Dinoso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epigenetic Silencing of Human Immunodeficiency Virus (HIV) Transcription by Formation of Restrictive Chromatin Structures at the Viral Long Terminal Repeat Drives the Progressive Entry of HIV into Latency

(2008) R. Pearson et al.   JOURNAL OF VIROLOGY

APOBEC proteins and intrinsic resistance to HIV-1 infection

(2008) M. H Malim   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES